Werewolf Therapeutics, Inc. current report, 31 August 2022

Full document

Werewolf Therapeutics, Inc. — Form 8-K Summary

Reporting period and context: The Form 8-K reports an auditor change under Item 4.01. The Audit Committee acted on August 31, 2022; the filing was signed September 7, 2022. The company’s common stock trades on Nasdaq under the symbol HOWL.

Auditor Change

  • Ernst & Young LLP was appointed as the independent registered public accounting firm for the fiscal year ending December 31, 2022, subject to customary client acceptance procedures.
  • Deloitte & Touche LLP was dismissed following a request-for-proposal process evaluating several accounting firms.
  • Deloitte’s audit reports covering the years ended December 31, 2021 and 2020 contained no adverse opinion, disclaimer, qualification, or modification relating to uncertainty, audit scope, or accounting principles.
  • The company reported no disagreements with Deloitte regarding accounting principles, financial statement disclosure, or audit scope or procedures during those fiscal years or the interim period through August 31, 2022.
  • The company also reported no reportable events during those periods.
  • Deloitte’s September 7, 2022 letter addressing these disclosures was filed as Exhibit 16.1.

Financial Metrics and Liquidity

This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating and financial metrics.

Outlook, Risks, and Unusual Items

  • The auditor transition is the principal unusual corporate event disclosed.
  • The filing does not provide management guidance, financial outlook, contingencies, or new operating risks.
  • The company stated that it had not consulted Ernst & Young during the relevant periods regarding accounting principles for specified transactions, potential audit opinions, disagreements, or reportable events.

Key Facts for Investors to Verify

  • Completion of Ernst & Young’s client acceptance procedures and its engagement for the 2022 audit.
  • The contents of Deloitte’s September 7, 2022 letter filed as Exhibit 16.1.
  • Subsequent SEC filings for any audit-related developments, restatements, internal-control matters, or financial results.
  • The company’s financial condition and liquidity, which are not disclosed in this Form 8-K.